ArticleIndian journal of ophthalmology2022

Commentary: A prospective, randomized, parallel group, double blind, multicenter study to compare the efficacy, safety and immunogenicity of Lupin's ranibizumab with lucentis in patients with neovascular age-related macular degeneration.

Lingam GopalPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.